American Century Companies Inc. Purchases 49,717 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

American Century Companies Inc. raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 99.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 99,831 shares of the specialty pharmaceutical company's stock after buying an additional 49,717 shares during the period. American Century Companies Inc. owned about 0.48% of ANI Pharmaceuticals worth $6,357,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Texas Permanent School Fund Corp increased its holdings in shares of ANI Pharmaceuticals by 1.3% in the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company's stock valued at $852,000 after purchasing an additional 178 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $261,000. Great Lakes Advisors LLC increased its holdings in shares of ANI Pharmaceuticals by 10.6% in the second quarter. Great Lakes Advisors LLC now owns 56,081 shares of the specialty pharmaceutical company's stock valued at $3,571,000 after purchasing an additional 5,359 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of ANI Pharmaceuticals by 4.7% in the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company's stock valued at $299,000 after purchasing an additional 211 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of ANI Pharmaceuticals by 15.4% in the second quarter. Rhumbline Advisers now owns 42,170 shares of the specialty pharmaceutical company's stock valued at $2,685,000 after purchasing an additional 5,617 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Trading Down 2.1 %

Shares of NASDAQ ANIP traded down $1.24 during midday trading on Wednesday, reaching $57.28. 297,545 shares of the stock were exchanged, compared to its average volume of 214,918. The business has a 50-day simple moving average of $60.89 and a two-hundred day simple moving average of $63.58. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of 36.58 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. The business had revenue of $138.00 million for the quarter, compared to analysts' expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm's revenue was up 18.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.06 EPS. As a group, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.58 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Raymond James raised their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a report on Wednesday, September 18th. StockNews.com lowered shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Truist Financial reaffirmed a "hold" rating and set a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $78.80.

Insider Transactions at ANI Pharmaceuticals

In related news, SVP Chad Gassert sold 20,000 shares of the company's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the transaction, the senior vice president now owns 193,226 shares in the company, valued at approximately $12,258,257.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, SVP Chad Gassert sold 20,000 shares of the company's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the transaction, the senior vice president now owns 193,226 shares in the company, valued at approximately $12,258,257.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Muthusamy Shanmugam sold 11,000 shares of the business's stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $63.38, for a total transaction of $697,180.00. Following the completion of the sale, the chief operating officer now directly owns 671,620 shares of the company's stock, valued at approximately $42,567,275.60. The disclosure for this sale can be found here. Insiders have sold 46,007 shares of company stock worth $2,911,790 in the last ninety days. Insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.